WO1994009755A1 - Procede et composition de prevention et/ou de traitement des pellicules et de la dermatite seborrheique - Google Patents
Procede et composition de prevention et/ou de traitement des pellicules et de la dermatite seborrheique Download PDFInfo
- Publication number
- WO1994009755A1 WO1994009755A1 PCT/EP1993/003060 EP9303060W WO9409755A1 WO 1994009755 A1 WO1994009755 A1 WO 1994009755A1 EP 9303060 W EP9303060 W EP 9303060W WO 9409755 A1 WO9409755 A1 WO 9409755A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- propylene glycol
- dandruff
- concentration
- scalp
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 208000001840 Dandruff Diseases 0.000 title claims abstract description 25
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 title claims abstract description 13
- 208000008742 seborrheic dermatitis Diseases 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 8
- 230000002265 prevention Effects 0.000 title claims description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 75
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 34
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 17
- 210000004761 scalp Anatomy 0.000 claims abstract description 14
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 239000002453 shampoo Substances 0.000 claims description 14
- 239000006210 lotion Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000000499 gel Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 3
- 239000004150 EU approved colour Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- IHOWSFVYYZTGSY-FOIRCHMTSA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)CC(O)(C(O)=O)CC(O)=O IHOWSFVYYZTGSY-FOIRCHMTSA-N 0.000 description 1
- PDNLXUROKBBMBE-BYOHNYAZSA-N (Z)-octadec-9-enoic acid (3R,4S,5R,6R)-3,4,5,6,7-pentahydroxyheptan-2-one Chemical compound CC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O PDNLXUROKBBMBE-BYOHNYAZSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- XVBRCOKDZVQYAY-UHFFFAOYSA-N bronidox Chemical compound [O-][N+](=O)C1(Br)COCOC1 XVBRCOKDZVQYAY-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- 229940110748 iodine / sodium iodide Drugs 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940044591 methyl glucose dioleate Drugs 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229940065287 selenium compound Drugs 0.000 description 1
- 150000003343 selenium compounds Chemical class 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012749 thinning agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
Definitions
- This invention relates to a method and composition for the prevention and/or treatment of scaling conditions of the scalp, such as dandruff, seborrhoeic dermatitis and psoriasis.
- Previously known methods for preventing and treating dandruff generally involve applying to the scalp various anti-dandruff agents contained in lotions, gels and shampoos.
- anti-dandruff agents include sulphur and selenium compounds, zinc pyrrithione and bacteriostatic and bacteriacidal agents such as, for example, hexachlorophene.
- the use of such anti-dandruff agents can give rise to adverse reactions, for example allergic reactions and erythematous lesions. Consequently, known anti-dandruff agents cannot be used in the long term and it is frequently found that dandruff symptoms recur.
- Known anti-dandruff agents are often difficult to formulate into cosmetically acceptable compositions .
- UK Patent No. GB 2,205,743 described the finding that propylene glycol is effective as an anti-dandruff agent and that a significant anti-dandruff effect may be observed following application of propylene glycol to the scalp, e.g. in the form of a lotion, gel or shampoo.
- Propylene glycol when used in accordance with the teachings of GB 2,205.743. avoided undesirable side effects which occur
- Propylene glycol has hitherto also been described for use as a diluent, thinning agent or vehicle for various pharmaceutical products including such products intended for topical use.
- carboxylic acid derivatives as active ingredients for treating keratinization defects.
- DE-A-2,758,484 describes the use of chenodesoxic acid as the active ingredient of anti-dandruff compositions including lotions, gels and shampoos.
- This specification mentions propylene glycol as an ingredient of such compositions but not as an active ingredient.
- compositions containing as active ingredient, inter alia arginine or arginine citrate.
- Such compositions can contain relatively small proportions of propylene glycol as diluent along with relatively larger
- GB-A-1,140,443 describes an antiseptic composition consisting of a saturated solution of salicylic acid in propylene glycol and in addition an antiseptic selected from sodium
- compositions of GB-A-1,140,443 generally contained more than 10 wt % of salicylic acid and the patent is not concerned at all with treatment of dandruff or seborrhoeic dermatitis.
- a possible reason for the actions of the combination therapy of the invention is that combinations of propylene glycol and
- salicylic acid have enhanced activity against Pityrosporum ovale, an organism that is now thought to be implicated as an aetiological agent responsible for both psoriasis and seborrhoeic dermatitis and possibly also dandruff. Further the combinations of propylene glycol and salicylic acid exhibit an enhanced keratolytic action.
- composition for use in the treatment of scaling conditions of the scalp including dandruff, seborrhoeic dermatitis and psoriasis which comprises as active ingredients, propylene glycol and salycylic acid. together with a topically acceptable excipient, the propylene glycol being present in a concentration of not greater than 50 wt % and the salicylic acid being present in a concentration of not greater than 10 wt %.
- the concentration of propylene glycol is from to 50 wt %, most preferably from 10 to 40 wt %.
- the salicylic acid is preferably present in a concentration of from 1 to 6 wt U, most preferably from 1 to 3 wt %.
- compositions according to the invention may be formulated in the form of solutions, lotions or gels suitable for topical application, or in the form of a shampoo.
- Compositions according to the invention may contain any conventional incidental adjuvents, for example, emolients, thickening agents, foaming agents, perfumes, colouring agents, stabilising agents, pH-adjusting agent and preservatives as well as water and/or ethanol.
- Shampoos in accordance with the invention typically contain conventional detergent and/or surfactants to provide any necessary foaming and cleansing action.
- the shampoos will contain perfuming ingredients and colouring agents and if desired other agents to make the product cosmetically acceptable, e.g. pearling agents, thickeners etc.
- a method of treating dandruff and/or seborrhoeic dermatitis and/or psoriasis which comprises applying a composition according to the invention to the affected region.
- compositions may be applied to the affected region at regular intervals of, for example. 1-5 and preferably 1-10 days.
- the shampoo should be left on the hair, for example, for 1-5 minutes to enable the therapeutic effects of the proplylene glycol and salicylic acid to occur.
- a lotion or gel also in accordance with the invention should be rubbed into the scalp and left in situ for 10 to 15 minutes. This combination of treatments has been found further to enhance the efficacy of the combination therapies of the invention.
- the invention thus further provides a kit for use in the treatment of scaling conditions of the scalp, including dandruff, seborrhoeic dermatitis and psoriasis, comprising
- a specific combination therapy according to the invention comprises
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
Composition destinée à être utilisée dans le traitement des desquamations du cuir chevelu telles que les pellicules, la dermatite séborrhéique et le psoriasis, cette composition renfermant comme ingrédients actifs du propylène glycol et de l'acide salicylique qui sont associés à un excipient acceptable topiquement, le propylène glycol ayant une concentration inférieure ou égale à 50 % en poids et l'acide salicylique une concentration inférieure ou égale à 10 % en poids.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP93924089A EP0666734A1 (fr) | 1992-11-03 | 1993-11-02 | Procede et composition de prevention et/ou de traitement des pellicules et de la dermatite seborrheique |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929223034A GB9223034D0 (en) | 1992-11-03 | 1992-11-03 | Method and composition for prevention and/or treatment of dandruff and seborrhoeic dermatitis |
| GB9223034.1 | 1992-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1994009755A1 true WO1994009755A1 (fr) | 1994-05-11 |
Family
ID=10724472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1993/003060 WO1994009755A1 (fr) | 1992-11-03 | 1993-11-02 | Procede et composition de prevention et/ou de traitement des pellicules et de la dermatite seborrheique |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0666734A1 (fr) |
| GB (1) | GB9223034D0 (fr) |
| WO (1) | WO1994009755A1 (fr) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995013048A1 (fr) * | 1993-11-12 | 1995-05-18 | The Procter & Gamble Company | Compositions desquamantes contenant de l'acide salicylique ainsi que des composes zwitterioniques |
| WO1996001101A1 (fr) * | 1994-07-01 | 1996-01-18 | The Procter & Gamble Company | Compositions de desquamation |
| WO1996011572A1 (fr) * | 1994-10-14 | 1996-04-25 | Sven Moberg | Composition antimicrobienne |
| FR2740679A1 (fr) * | 1995-11-03 | 1997-05-09 | Letourneur Raymond | Composition de shampooings et traitements a base d'eau de pluie |
| US5681852A (en) * | 1993-11-12 | 1997-10-28 | The Procter & Gamble Company | Desquamation compositions |
| WO1997048374A3 (fr) * | 1996-06-20 | 1998-02-05 | Procter & Gamble | Systemes de diffusion de parfum dans des compositions de savon liquide |
| WO1997048375A3 (fr) * | 1996-06-20 | 1998-02-05 | Procter & Gamble | Systeme de liberation de parfum, incorpore a des compositions liquides pour le nettoyage de la peau |
| US5821237A (en) * | 1995-06-07 | 1998-10-13 | The Procter & Gamble Company | Compositions for visually improving skin |
| US5834409A (en) * | 1995-03-31 | 1998-11-10 | Colgate-Palmolive Company | Scalp care products containing anti itching/anti irritant agents |
| DE10205193A1 (de) * | 2002-02-08 | 2003-08-21 | Beiersdorf Ag | Diolhaltige Reinigungszubereitungen |
| EP1595530A1 (fr) * | 2004-05-10 | 2005-11-16 | L'oreal | Composition cosmétique ou dermatologique à base d'un tensioactif, d'un acide monocarboxlique et d'un polyol |
| FR2943896A1 (fr) * | 2009-04-01 | 2010-10-08 | Oreal | "roll-on" a forte teneur en acide salicylique. |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53145925A (en) * | 1977-05-23 | 1978-12-19 | Kanebo Ltd | Solid composition for softening corneous tissue |
| US4514385A (en) * | 1981-10-05 | 1985-04-30 | Alcon Laboratories, Inc. | Anti-acne compositions |
| DD225913A1 (de) * | 1984-06-22 | 1985-08-14 | Miltitz Chem Werk | Antibakteriell komedolytisch wirkende substanzkombination |
| FR2585575A1 (fr) * | 1985-08-01 | 1987-02-06 | Pf Medicament | Compositions pharmaceutiques a activite keratolytique sous forme de gel comportant de l'acide salicylique hydro-alcoolique |
| WO1987004617A1 (fr) * | 1986-02-04 | 1987-08-13 | Sven Moberg | Compositions pharmaceutiques contenant comme principaux constituants actifs du propylene glycol et/ou du polyethylene glycol et de l'uree, et leur utilisation |
| WO1989000853A1 (fr) * | 1987-07-25 | 1989-02-09 | Konrad Minninger | Agent contenant de l'acide salicylique pour le traitement de dermatoses squameuses |
| EP0337289A1 (fr) * | 1988-04-10 | 1989-10-18 | Konrad Minninger | Composition pharmaceutique contenant du dithranol pour le traitement des maladies exfoliatives de la peau |
-
1992
- 1992-11-03 GB GB929223034A patent/GB9223034D0/en active Pending
-
1993
- 1993-11-02 EP EP93924089A patent/EP0666734A1/fr not_active Withdrawn
- 1993-11-02 WO PCT/EP1993/003060 patent/WO1994009755A1/fr not_active Application Discontinuation
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53145925A (en) * | 1977-05-23 | 1978-12-19 | Kanebo Ltd | Solid composition for softening corneous tissue |
| US4514385A (en) * | 1981-10-05 | 1985-04-30 | Alcon Laboratories, Inc. | Anti-acne compositions |
| DD225913A1 (de) * | 1984-06-22 | 1985-08-14 | Miltitz Chem Werk | Antibakteriell komedolytisch wirkende substanzkombination |
| FR2585575A1 (fr) * | 1985-08-01 | 1987-02-06 | Pf Medicament | Compositions pharmaceutiques a activite keratolytique sous forme de gel comportant de l'acide salicylique hydro-alcoolique |
| WO1987004617A1 (fr) * | 1986-02-04 | 1987-08-13 | Sven Moberg | Compositions pharmaceutiques contenant comme principaux constituants actifs du propylene glycol et/ou du polyethylene glycol et de l'uree, et leur utilisation |
| WO1989000853A1 (fr) * | 1987-07-25 | 1989-02-09 | Konrad Minninger | Agent contenant de l'acide salicylique pour le traitement de dermatoses squameuses |
| EP0337289A1 (fr) * | 1988-04-10 | 1989-10-18 | Konrad Minninger | Composition pharmaceutique contenant du dithranol pour le traitement des maladies exfoliatives de la peau |
Non-Patent Citations (4)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 90, no. 18, 30 April 1979, Columbus, Ohio, US; abstract no. 142079, "antikeratilizing cosmetic compositions" * |
| DATABASE WPI Week 8549, Derwent World Patents Index; AN 85-303718 * |
| S.T.N., File Supplier, KARLSRUHE, DE, File Chemical Abstracts, vol103, nŸ 220624 & JP-A-59088421, pub. 22-5-84 see the abstract * |
| S.T.N., File Supplier, KARLSRUHE, DE, File Embase, an=83021705 'psoriasis', Anderson, 1982 see the abstract * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5652228A (en) * | 1993-11-12 | 1997-07-29 | The Procter & Gamble Company | Topical desquamation compositions |
| WO1995013048A1 (fr) * | 1993-11-12 | 1995-05-18 | The Procter & Gamble Company | Compositions desquamantes contenant de l'acide salicylique ainsi que des composes zwitterioniques |
| US5849728A (en) * | 1993-11-12 | 1998-12-15 | The Procter & Gamble Company | Desquamation compositions |
| US5681852A (en) * | 1993-11-12 | 1997-10-28 | The Procter & Gamble Company | Desquamation compositions |
| CN1107495C (zh) * | 1994-07-01 | 2003-05-07 | 纺织研究院公司 | 去屑组合物 |
| WO1996001101A1 (fr) * | 1994-07-01 | 1996-01-18 | The Procter & Gamble Company | Compositions de desquamation |
| WO1996011572A1 (fr) * | 1994-10-14 | 1996-04-25 | Sven Moberg | Composition antimicrobienne |
| US5834409A (en) * | 1995-03-31 | 1998-11-10 | Colgate-Palmolive Company | Scalp care products containing anti itching/anti irritant agents |
| US5821237A (en) * | 1995-06-07 | 1998-10-13 | The Procter & Gamble Company | Compositions for visually improving skin |
| FR2740679A1 (fr) * | 1995-11-03 | 1997-05-09 | Letourneur Raymond | Composition de shampooings et traitements a base d'eau de pluie |
| WO1997048374A3 (fr) * | 1996-06-20 | 1998-02-05 | Procter & Gamble | Systemes de diffusion de parfum dans des compositions de savon liquide |
| WO1997048375A3 (fr) * | 1996-06-20 | 1998-02-05 | Procter & Gamble | Systeme de liberation de parfum, incorpore a des compositions liquides pour le nettoyage de la peau |
| US5804538A (en) * | 1996-06-20 | 1998-09-08 | The Procter & Gamble Company | Perfume delivery systems in liquid personal cleansing compositions |
| DE10205193A1 (de) * | 2002-02-08 | 2003-08-21 | Beiersdorf Ag | Diolhaltige Reinigungszubereitungen |
| EP1595530A1 (fr) * | 2004-05-10 | 2005-11-16 | L'oreal | Composition cosmétique ou dermatologique à base d'un tensioactif, d'un acide monocarboxlique et d'un polyol |
| FR2943896A1 (fr) * | 2009-04-01 | 2010-10-08 | Oreal | "roll-on" a forte teneur en acide salicylique. |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9223034D0 (en) | 1992-12-16 |
| EP0666734A1 (fr) | 1995-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10688117B2 (en) | Topical wash composition for use in acne patients | |
| US4514385A (en) | Anti-acne compositions | |
| US6162774A (en) | Skin wash composition | |
| RU2647479C2 (ru) | Композиция для умывания в виде эмульсии, содержащая бпо | |
| US20110082118A1 (en) | Onychomycosis Treatment Delivery System | |
| US6120756A (en) | Topical anionic salicylate for disorders of the skin | |
| WO1994009755A1 (fr) | Procede et composition de prevention et/ou de traitement des pellicules et de la dermatite seborrheique | |
| US20060159714A1 (en) | Use of an antioxidant in a dermatological and/or cosmetic composition | |
| CN111936130B (zh) | 包含锶和甲基磺酰基甲烷（msm）的局部制剂及治疗方法 | |
| WO2014041542A2 (fr) | Compositions topiques destinées au traitement de l'acné | |
| US5667790A (en) | Aluminum chlorhydrate as a treatment for acne and rosacea | |
| Breneman et al. | Successful treatment of acne vulgaris in women with a new topical sodium sulfacetamide/sulfur lotion. | |
| KR20020011976A (ko) | 칸디다 알비칸스가 증식한 피부 부분으로부터 여드름 및딱지를 제거하는 피부 청결 방법 | |
| EP0086228B1 (fr) | Utilisation du peroxyde de carbamide pour le traitement de l'acne vulgaire | |
| US6485714B1 (en) | Use of salicylic acid for regulating hyperpigmented spots | |
| JPH07267869A (ja) | 皮膚病治療薬及び治療方法 | |
| JPH03178922A (ja) | フケ抑制剤組成物 | |
| WO2006119540A1 (fr) | Preparation destinee a traiter le psoriasis | |
| GB2302808A (en) | Propylene glycol with low potency corticosteroids for topical treatment of the scalp | |
| GB2205743A (en) | Cosmetic composition for prevention and/or treatment of dandruff | |
| Stough et al. | New beneficial agents in the treatment of acne vulgaris and seborrheic dermatitis | |
| JP2826141B2 (ja) | フケ抑制剤組成物 | |
| WO2024144577A1 (fr) | Produit de nettoyage de la peau efficace contre le brunissement local | |
| JPH03178921A (ja) | フケ抑制剤組成物 | |
| RU2406479C1 (ru) | Лечебно-профилактическая моющая композиция с пиритионом цинка и способ ее получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1993924089 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref country code: US Ref document number: 1995 428198 Date of ref document: 19950620 Kind code of ref document: A Format of ref document f/p: F |
|
| WWP | Wipo information: published in national office |
Ref document number: 1993924089 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1993924089 Country of ref document: EP |